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1INTRODUCTION
Infectious diseases have been a constant yet evolving problem in
the renal transplant recipients. The reduction in the incidence and
severity of complications related to infection, can be attributed to
multiple factors: improved surgical techniques, alterations and
improvement in immunosuppressive regimens, institution of
prophylactic antimicrobial agents, better diagnostic
armamentarium, and the availability of more effective means of
preventing and treating certain types of infection. This is reflected
by the fact that during the first decades of the renal transplantation
era, serious infectious complications developed in up to 70% of
patients following transplant, resulting in fatal outcomes in as
many as 11% to 40% of cases. (1, 8, 9, 11, 12, 13, 16) Recent
studies have described an incidence of 15% to 44%, with mortality
rate due to infections of less than 5% (2,3, 4,5, 6, 7, 10, 13, 14, 16
and 17).
Urinary tract infection continues to be the most common infection
among renal transplant patients in Christian Medical College
hospital. Infections continue to cause post-transplant morbidity and
2remains a leading cause of death of renal allograft recipients at all
points in the post-surgical course (8, 10, 13 and 15). The
prevention and effective treatment of infectious complications
remain major concerns of the transplant clinicians.
The high incidence of urinary tract infection (UTI) following
renal transplant patients at our center has been of concern for the
transplant team. A retrospective study of the first 30 transplants
done in 2006 showed a 50% incidence of bacteriuria, hence a
prospective study was planned to determine the incidence,
predisposing factors if any, and ways to decrease them.
This study was initiated as a part of continuing efforts to improve
the care of renal transplant recipients and to explore ways to
decrease postoperative morbidity arising specifically out of
infections in the urinary tract.
3AIMS AND OBJECTIVES
The objective of this study was to evaluate specific strategies to
reduce the incidence of bacteriuria after ascertaining the true
burden of the problem in a prospective and controlled fashion.
The primary objective of this study was to prospectively
determine in a randomized manner, whether gentamicin
instillation into the urinary bladder at renal transplant, reduced the
incidence of UTI during first 2 months following transplant
and/or if there was a delay in the incidence of UTI in the same
time period.
The secondary aim of the study was to evaluate whether a per-
operative dose of antibiotic decreased the incidence of such
infections in those with sterile urine prior to the transplant.
4REVIEW OF LITERATURE
POST TRANSPLANT UTI:  BURDEN OF THE PROBLEM.
Urinary Tract infection is the most common infection seen after
kidney transplantation. The exact incidence remains a subject of
debate with different studies reporting widely varying incidence
rates (18,19,20). While the effects of early or late UTI after kidney
transplantation on graft life and patient mortality has been
controversial, some studies report adverse effects of UTI on both
parameters (21).  Other studies have failed to demonstrate a causal
relationship though (21, 22). Risk factors for developing UTI after
kidney transplantation have been numerous and varied. They have
included female recipient gender, white or black race, deceased
donor source of kidney, reflux kidney disease, and use of
azathioprine or cyclosporin A (19, 23).
In a study involving analysis of the USRDS database for UTI in
adult kidney transplant recipients; the cumulative incidence of
early UTI was 17% for both genders (A). By 3 years after
transplantation, the cumulative incidence was 60% in adult female
recipients and 47% in adult male recipients. Recent articles from
single centers have also reported similar frequencies. In a study of
5adults, the occurrence of late UTI more than 6 months after
transplantation was associated with a significantly higher risk for
both graft loss and patient death. Factors that were associated with
a higher risk for developing UTI after kidney transplantation in the
adult population included female sex, black race, primary renal
disease being chronic obstruction, chronic pyelonephritis, or
polycystic kidney disease; recipient history of diabetes; and acute
rejection episode in the first 6 months (24).
PHYSIOLOGY OF THE BLADDER
The uroepithelium lines the inner surface of the renal pelvis, the
ureters, and the urinary bladder, where it forms a tight barrier that
allows for retention of urine, while preventing the unregulated
movement of ions, solutes, and toxic metabolites across the
epithelial barrier. In the urinary bladder, this barrier must be
maintained even as the organ undergoes cyclical changes in
pressure as it fills and empties. Recent analysis of the
uroepithelium has provided information on how detergent-
insoluble membrane/protein domains called plaques are formed at
the apical plasma membrane of the surface umbrella cells, how
mechanical stimuli such as pressure alter exocytic and endocytic
traffic in epithelial cells such as umbrella cells, and how changes in
6pressure are communicated to the underlying nervous system.
Epithelial cells line the inner surfaces of organ systems and the
urogenital tract is no exception. In the case of the urinary tract
(including the renal pelvis, ureters, and bladder), the surface is
coated by a specialized epithelium called the uroepithelium. The
uroepithelium is stratified and is comprised of three cell types
including basal cells, intermediate cells, and umbrella cells. Basal
cells are small (10 _m in diameter), form a single layer that
contacts the underlying connective tissue and capillary bed, and
serve as precursors for the other cell layers. Their estimated half-
life is 3–6 months. (25,26). Intermediate cells are pyriform in
shape (10–25 am in diameter), sit above the underlying basal cells,
and form a layer that appears in cross-section anywhere from one
to several cell layers thick. The outermost umbrella cell layer is
comprised of very large polyhedral cells with diameters of
25–250 am. Although umbrella cells are long lived, they are
rapidly regenerated when the uroepithelium is damaged. This
regeneration can result from cell division within any of the three
cell layers, and generation of the multinucleate umbrella cells is
likely due to intermediate cell–cell fusion (26).
A primary function of the uroepithelium is to form a barrier that
7prevents entry of pathogens and selectively controls the passage of
water, ions, solutes, and large macromolecules across the mucosal
surface of the cell into the underlying tissue. Barrier function
depends, in part, on the presence of specialized membrane domains
that form a seal between the plasma membranes of adjacent
epithelial cells. In the case of the uroepithelium, high resistance
tight junctions are found in the umbrella cell layer that effectively
divide the cell surface of these cells into apical and basolateral
membrane domains (27). In addition, the apical membrane of
umbrella cells has a unique lipid and protein composition that also
contributes to the low permeability of this membrane domain to
water and solutes (27-29)
The bladder epithelium was long treated as an impermeable
cellular plastic coating that allowed for urine storage, and the
majority of analyses of the lower urinary tract have focused on the
bladder musculature and innervation. A renewed interest in the
uroepithelium indicates that it can alter the ion and protein
compositions of the urine as well as selectively allow transport of
substances into the body via the bladder wall (27,30,31).
8THE ROLE OF THE GAG LAYER
The GAG layer has been the controversial subject of urothelial
barrier function. Parsons and associates (32) observed that after
pretreatment with protamine sulfate there was an increase in rabbit
urothelial permeability, both in vivo and in vitro, to water, urea,
and calcium. This effect was reversed with pentosanpolysulfate
(PPS). They concluded that the protamine sulfate affected the
GAG layer, and that this was repaired by PPS. However no
microscopic evidence of the anatomical changes were borne out in
this paper. Nickel and colleagues, who performed the study (33)
compared PPS and heparin and hyaluronic acid as treatment
groups. The authors concluded that heparin was the best of the
three agents in efficacy, but pointed out that this may be due to its
anti-inflammatory properties. Others have suggested that the
primary role of the GAG layer may be more in line with an
antibacterial adherence function, as outlined by Hanno and
associates. (34) The GAG layer may also be important for the
formation and attachment of particulates to the urothelium and
stone formation. (35,36)
However, there are several problems with the theory of the GAG
layer being the primary urothelial plasma barrier. The first is that
protamine sulfate can be used as a cytodestructive agent. (37)
9Second, the GAG layer does not prevent small molecules such as
amiloride from reaching, and subsequently interfering with, the
sodium channels expressed on the surface of the umbrella cells.
Third, the polyene antibiotic nystatin can reach the urothelium, as
evidenced by increases in the short-circuit currents and reduction
in transepithelial resistance to insignificant values as it generates
nonspecific cation pores in the cholesterol-containing luminal
membrane of the umbrella cells. Fourth, using microelectrodes, the
first resistive barrier found is upon entry into the cell. Fifth,
addition of monomeric arginine or polyvalent cations does not alter
transepithelial ion permeability based on electrical measurements.
Sixth, use of hydrolytic agents such as neurominidase,
hyaluronidase, or chondroitonase, or a proteolytic agent such as
trypsin or kallikrein (to deliberately strip the urothelium of the
GAG layer) does not alter the ability of protamine to increase the
urothelial permeability. (38) This implies that the protamine does
not act at the level of the GAG layer but rather at the level of the
luminal umbrella cells. Regardless, one cannot discount the
possibility that under certain conditions the GAG layer may play a
supportive role in barrier function. These data help infer the fact
that the GAG layer probably has a prominent supportive role than
as a primary barrier which may well be the role of the urothelium.
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ROLE OF TRANSITIONAL EPITHELIUM IN DRUG
TRANSPORT AND INFECTION
The apical surface of umbrella cells contains unique structural and
biochemical features. Under an electron microscope the surface of
the umbrella cells, appears undulating and a tight junctional ring
surrounds each cell. Raised ridges, also called hinges or
microplicae, and intervening areas called plaques, cover this
surface. The arrangement of hinges and plaques give the apical
surface its characteristic scalloped appearance, which is apparent
when the apical surface of cross-sectioned umbrella cells is viewed
by transmission electron microscopy. The hinge areas are not well
understood, but contain at least one unique protein called urohingin
(39), and presumably all other non-plaque proteins. Plaques are
thought to occupy approximately 70–90% of the surface of the
umbrella cell (26,40,41).
The membrane associated with the hinge and plaque regions is
highly detergent insoluble, even in relatively harsh detergents like
sarkosyl (42). The detergent insolubility may reflect the unusual
lipid composition of this membrane, which is rich in cholesterol,
phosphatidyl choline, phosphatidyl ethanolamine, and cerebroside
– a lipid profile similar to myelin (43). Cholesterol-rich and
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detergent-insoluble membranes form ‘rafts’ and cavalla (44).
Essentially, the entire apical surface of the umbrella cell is
composed of two lipid raft sub domains: plaques and hinges, which
play a prime role in its insolubility.
The membrane associated with the plaque regions, have two layers
(leaflets) and the outer leaflet appears to be twice as thick as the
inner leaflet, thus forming an asymmetric unit membrane (AUM)
(40,45,56). The AUM is composed of a Para crystalline array of
16-nm diameter AUM particles and   exhibits six-fold symmetry.
They are composed of an inner ring containing six large particles
and an outer ring containing six small particles, and each subunit
forms a twisted ribbon structure (46). A plaque is comprised of
1000 to 3000 AUM particles.
 Potential constituents of the AUM particles include the uroplakins
(UPs), a family of at least five proteins including the tetraspan
family members UPIa and UPIb, and the type I single-span
proteins UPII, UPIIIa, and UPIIIb (47,48). UPIa, UPII, UPIIIa, and
UPIIIb are only expressed in the uroepithelium and are
concentrated in the umbrella cell layer UPIa serves as a receptor
for uropathogenic Escherichia coli (49,50, 51). How UPs combine
to generate the six-fold symmetry of the AUM particles is
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currently unknown. Furthermore, the currently described UPs may
not be the sole constituents of AUM particles, as there are other
proteins associated with plaques, such as antigen recognized by the
AE-31 monoclonal antibody that have not been characterized (52).
ROLE OF TRANSITIONAL EPITHELIUM IN INFECTION
It is understandable from above that integrity of epithelium is
essential also for prevention of infection. Normal urinary
constituents do not therefore interfere with bladder permeability
and changes within the physiological range for urine pH, calcium,
or urea concentrations have minimal effects on the barrier function
of the urothelium as determined from measurements of the
transepithelial resistance (53). Nonphysiological concentrations of
these substances, e.g., acid pH, low calcium, or high urea (4, 51),
cause an increase in the ion permeability of the urothelium. The
sites of increased ion permeability are at the apical membrane and
tight junction. After pH, calcium, or urea return to normal values,
the permeability of the urothelium returns to control values (26).
Similar situation ensues in cases of infection. A number of
nonphysiological factors and bacteria alter the barrier function of
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the urothelium. These include bacterial products such as
amphotericin B, nystatin, gramicidin, polymyxin B, and perhaps
alpha -hemolysin as well as positively charged proteins released
from eosinophils and found in sperm (histones and protamine;
(54). All of these substances increase the ion permeability of the
urothelium by interacting with the apical membrane and causing a
nonselective increase in membrane ion permeability. If the
increase in membrane permeability persists, cell swelling and lysis
will occur. The loss of cells from the epithelial layer results in a
loss of barrier function.
RESPONSE OF BLADDER EPITHELIUM TO FILLING
 
The response of the uroepithelium to cyclical changes in
hydrostatic pressure as the bladder fills and empties has been a
subject of considerable research. In the bladder, pressure rises in a
tri-physic manner as the organ fills with urine. The first rise occurs
rapidly and then pressure remains relatively constant for an
extended period of time called the storage phase. The storage
phase is followed by the maturation phase, which is characterized
by a rapid rise in bladder pressure, punctuated by large spikes in
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pressure as the smooth muscle contracts. Upon voiding, the
pressure returns to baseline and the process begins anew. A crucial
aspect of the barrier function of the uroepithelium is that it must be
maintained in the face of these changes in hydrostatic pressure.
The increased urine volume is accommodated by the uroepithelium
in at least two ways. The chief mechanism is likely to be unfolding
of the mucosal surface, which is highly wrinkled in the empty
bladder. The other mechanism occurs at the cellular level and
involves transitions in the morphology and function of the
uroepithelium. As the bladder fills, the uroepithelium becomes
thinner, apparently the result of intermediate and basal cells being
pushed laterally to accommodate the increased urine volume (26).
The umbrella cells undergo a large shape change that involves
progression from a roughly cuboidal morphology in the empty
bladder to one that is flat and squamous in the filled bladder (26).
MODELS OF SUBSTANCE TRANSPORT
In the classical model for vesical dynamics, the umbrella cell shape
transformation is hypothesized to be accompanied by discoidal/
fusiform vesical exocytosis. This would increase the apical surface
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area of the umbrella cell and the overall surface area of the
bladder, allowing the bladder to accommodate additional urine
volume (55,56). Upon voiding, it is hypothesized that apical
membrane added during filling is rapidly internalized, replenishing
the pool of discoidal vesicles. An alternative model proposes that
there are no changes in umbrella cell surface area and, instead,
changes in umbrella cell shape are accomplished by
folding/unfolding of the apical plasma membrane (57).
EXOCYTOSIS AND ENDOCYTOSIS IN RESPONSE TO
INCREASED HYDROSTATIC PRESSURE
It is widely believed that pressure induces exocytosis of
discoidal/fusiform vesicles, resulting in increased umbrella cell
apical surface area. Recent studies have demonstrated isolated
tissue that increased hydrostatic pressure stimulates a 50% increase
in apical surface area that is coupled with a significant decrease in
vesicle surface area (55). This change occurs gradually (over a 5-h
time period), indicating that exocytosis is a graded process.
 Studies with specialized assays  have demonstrated that increased
hydrostatic pressure not only stimulates exocytosis, but also
stimulates rapid endocytosis (55). The endocytosed membrane
components including UPs are likely delivered to lysosomes,
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where they are degraded (55), although this has not been formally
proven. Whether recycling of internalized membrane is occurring
is also unknown. Apparently, the rates of endocytosis and
exocytosis are such that the net effect is to add membrane to the
apical surface of the cell.
These data lead to a refinement of the classical model for vesicle
transport to include an endocytic pathway that operates
simultaneously with the exocytic pathway (55).
At first glance, the fact that hydrostatic pressure would
simultaneously induce exocytosis and endocytosis seems illogical;
however, hydrostatic pressure-induced endocytosis would
modulate the increase in apical surface area brought about by
exocytosis, and it would ensure turnover of membrane components
such as AUM particles.
 As described earlier, AUM particles may play important roles in
barrier function and plasma membrane events. Furthermore,
endocytosis and exocytosis are coupled in other cell types, such as
neurons, where these two processes maintain the unique
composition of the presynaptic membrane (59). Not much is
known about the pathways for endocytosis (60) but umbrella cells
may provide a model system to define the machinery that drives
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them and study how they are regulated.
 Recent evidence indicates that exposing the apical surface of the
epithelium to hypertonic solutions stimulates apical endocytosis
(61), but the mechanism is unknown, and endocytosis that
accompanies return from hypotonic medium (which causes cell
swelling) to isotonic medium is blocked in cells treated with the
actin disrupting agent cytochalasin B (62), indicating a role for
ac t in  in  umbre l l a  ce l l  ap i ca l  endocy tos i s .
EVENTS FOLLOWING VOIDING
 The classical model proposes that, upon voiding, apical membrane
added during filling is rapidly endocytosed. Although highly
likely, the current evidence is scant. However, filling the bladder
increases hydrostatic pressure and induces the hydrostatic
pressure-stimulated endocytosis described above (55). Other
evidence comes from studies in which endocytosis was studied in
tissue placed in hypotonic, then isotonic buffers (63); however, the
physiological significance of this experimental manipulation is
unclear. Finally, there is evidence that short-term application of
hydrostatic pressure (for 5 min) across isolated uroepithelium
increases surface area, and this increase returns to baseline when
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the pressure is released, presumably the result of endocytosis (62).
The intracellular fate of membrane internalized after voiding is an
open question. The classical model proposes that it serves to
reestablish the population of discoidal vesicles (64,58). However,
there are few data that support this conclusion. In fact, endocytosed
marker proteins (including fluid-phase and membrane-bound
lectins) only label a small fraction of the total discoidal vesicle
pool (65, 58, 66), indicating that the majority of discoidal vesicles
may be formed de novo along the biosynthetic pathway.
SENSING BLADDER FULLNESS: CROSS-TALK BETWEEN
THE UROEPITHELIUM AND THE NERVOUS SYSTEM
 
A growing body of evidence indicates that epithelia exposed to
mechanical stimuli, such as those lining the gut, blood vessels,
airways of the lung, and lower urinary tract, receive and transmit
signals to submucosal neurons (67,68). In the case of the bladder,
there is evidence that the uroepithelium may communicate bladder
fullness to the underlying nervous system through a paracrine
signaling pathway involving ATP release (67, 68).
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SUMMARY AND PERSPECTIVES
The composition of urine is markedly different from plasma, with
urine osmolality ranging from 50 to 1200 Osmol, a pH ranging
between 4.5 and 10, and containing high concentrations of
ammonia, urea, as well as other toxins. In humans, the bladder
must store this urine for prolonged periods of time without
permitting the passage of highly permeable molecules such as
ammonia into the bloodstream. The barrier to ion, solute, and toxin
flux is formed by the uroepithelium, which lines the inner surface
of the bladder and must also adapt to large variations in pressure as
the bladder fills and empties.
In addition, study of the uroepithelium is providing clues to how
epithelial cells sense mechanical stimuli such as pressure, and
transduce changes in these stimuli into cellular events such as
membrane traffic. Increased pressure, for example, stimulates
exocytosis and endocytosis in umbrella cells. There are other
factors, which promote or prevent bacterial or chemical
translocation across the urinary epithelium. Finally, the
uroepithelium interfaces with an underlying nervous system, and
bidirectional signaling between these two systems may
communicate the degree of bladder filling, and may allow the
nervous system to modulate uroepithelial barrier function.
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Knowledge of these mechanisms is being used to fight urinary
infections and promote bladder as a route of drug administration in
a variety of pathogenic states.
BLADDER AS A ROUTE OF DRUG ADMINISTRATION.
Intravesical delivery of drugs have been used for treatment of
Overactive bladder e.g. oxybutinin, and Transitional cell
carcinoma e.g. Mitomycin With the possible exception of latter
treatment of other pathological states via the bladder route have
never really gained popularity as this method of delivery is just too
cumbersome, as it requires repeated manipulation (bladder
catheterization 3 to 4 times a day) of the lower urinary tract.
Unless one is considering a patient already on clean intermittent
self-catheterization, most patients will not accept this complex
form of therapy.
In case of drugs like oxybutynin very high levels can be achieved
with minimal systemic side effects. The reason lies in the fact that
the majority of the effects on the salivary gland are produced by
the oxybutynin metabolite desethyloxybutynin, which is produced
not only by first-pass metabolism in the liver but also by direct
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cytochrome P450 metabolism in the gut wall. (69) With
oxybutynin XL, the drug is delivered at a steady rate for 24 hours,
spending only 3 to 5 hours in the upper gut. (70) Therefore gut
wall metabolism and first-pass metabolism in the liver are
proportionally reduced, and subsequently one finds a reduced ratio
of metabolite to parent compound systemically. This means one
can achieve greater efficacy on the bladder with less dry mouth.
Antineoplastic agents like Mitomycin C usually have 1 time use
and can be instilled at surgery and the scope of action mainly
remains local hence is an attractive intravesical option.  
For antibiotics too instillation can be an attractive form of
brachytherapy that has distinct advantages. It avoids GI upset and
alteration of gut flora can be avoided.
The principal concerns remained about effectiveness, bladder
epithelial irritation, toxic absorption, and the inconvenience of
having to pass a catheter. These perceptions are reflected in many
of the early studies of instilled antibiotics that focused on
individuals who were irrigated through indwelling catheters as a
prophylactic measure against perioperative cystitis (72, 72, 73).
Chamberlain and Needham investigated polymixin B, bacitracin
and neomycin irrigations in women who underwent hysterectomy.
Giannoni et al (73) evaluated 300 men who were irrigated with
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povidone-iodine after transurethral resection of the prostate. These
studies and others found fewer episodes of symptomatic bacteriuria
while patients were on irrigation, but also confirmed suspicions
about possible limitations of the technique.  Certain agents such as
acetic acid irritated the bladder epithelium and caused ulcers. (74)
Others such as chlorhexidine were poorly effective against
common iatrogenic pathogens such as Pseudomonas. (75) 
If constant, therapeutic levels of drugs in the bladder can be
achieved without repeated instrumentation, this would provide an
extremely effective regimen to treat bladder pathologies. A similar
situation can be envisaged in case of antimicrobials in UTI wherein
significantly higher levels can be maintained in the bladder for
long duration in susceptible individuals without risking toxicity of
the drug in question. 
AMINOGLYCOSIDES: THE PHARMACOLOGY, SPECTRUM
AND INTRAVESICAL USE
The use of gentamicin sulfate intravesically is nothing new.
Though the safety of the drug when used intravesically has never
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been in doubt, its efficacy remains to be validated in large-scale
studies. Literature availability so far has been limited to small
studies and anecdotal reports.
Mc Guire et al (76) empirically used gentamicin sulfate for
prophylaxis and treatment of bacterial cystitis for ten years in adult
spinal-cord-injured patients on CIC who periodically experienced
bacterial cystitis if not kept on oral antibiotics, and sometimes, in
spite of medication. The infections were asymptomatic or
presented with cloudy malodorous urine or new-onset urinary
leakage. None were febrile, but all had bacteriuria and all had
positive urine cultures. When Gentamicin instillation began, the
urine cleared, cultures would become negative, and patients could
stop taking oral agents. About 10 percent of all adult spinal-cord-
injured patients evaluated by the authors, utilized intravesical
gentamicin in this manner (84).
Gentamicin sulfate is an ideal intravesical antibiotic. It is a proven
bactericide against most genitourinary pathogens (especially
Pseudomonas species and other gram-negative organisms). First
isolated as a derivative of Micromonospora purpurea in 1963,
gentamicin has been widely used intravenously. (78)
Commercially synthesized as gentamicin sulfate, it is highly
cationic and does not easily cross lipid membranes. When
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administered orally, it is poorly absorbed, although absorption has
been noted when exposed to serosal surfaces, burns, and wounds
during lavage or irrigation. (78) Findings by the same group of
authors in the rat model suggest that severe inflammation does
increase absorption from the bladder. The canine and human data
suggest that high intravesical pressure and vesicoureteral reflux
without inflammation do not they predispose to increased
absorption. However, although significant levels of absorbed
gentamicin did not develop in any patient, further studies are
needed to determine if monitoring of serum gentamicin levels is
necessary in patients with bladder augmentation, renal failure, or
those taking immunosuppressive drugs. The effects of storage
conditions are important to the usefulness of gentamicin sulfate as
an intravesical agent. For outpatients the convenience and
economy of being able to prepare liter quantities of irrigation
solution and store at room temperature is appealing. It is known
that GS is more potent in an alkaline environment. Increased
acidity can increase the minimal concentration needed to inhibit
the growth of gram-negative bacilli eight to thirtytwo-fold. (79)
Prolonged exposure to higher temperatures (> 20 C), oxygen, and
plastics has been identified as a factor that can lead to a loss of
antimicrobial activity. (80,81). The in vitro data demonstrate that
gentamicin sulfate can be safely stored without refrigeration or
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alkalinization and remains potent for up to two months.
Intravesical instillation of gentamicin sulfate is safe and effective.
For patients who perform CIC it should be considered as a route of
prophylaxis against recurrent simple bacterial cystitis. It obviates
the need for oral agents and their attendant risks. This evaluation of
gentamicin has established the criteria by which other potential
intravesical antimicrobial agents can be judged: it has a low risk of
absorption across a spectrum of clinical situations, it is highly
effective against likely pathogens, and it demonstrates prolonged
stability without special storage conditions.
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MATERIALS AND METHODS
The authors sought to determine whether instillation of Gentamicin
during bladder distention affected the incidence of urinary tract
infections in the immediate post operative period following renal
transplantation. The concept of antibiotic instillation, though not
new has not been tried using gentamicin, especially in a setting of
renal transplant patients. The fact that it is an urinary antimicrobial,
effective against most pathogens and its systemic use being
precluded in renal failure patients prompted its choice as the agent
in this study. A randomized, double-blinded placebo controlled
study was designed to see if aminoglycosides could prevent
development of urinary tract infections in renal transplant patients
in the immediate post operative period.
SAMPLE SIZE DETERMINATION AND STATISTICAL
ANALYSIS
The sample size was calculated with the aid of a statistician.
Considering a 50% decrease in incidence of UTI as significant in
 the treatment arm and a power of 90% a figure of 170 was arrived at.
 Thus a total of 170 patients were to be randomized and placed in the
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plain saline arm, or the saline plus Gentamicin arm. Block randomization
with blocks of size varying between 4 to 8 were allocated to each group
and sub stratification into the two units were made. The randomization
was performed in the department of Biostatistics, using computer-
generated numbers. This was sealed and delivered to the pharmacist who
prepared the vials containing the Gentamicin or placebo and packed as
mentioned above. The statistician and the pharmacist had no role in the
actual conduct of the trial whatsoever. The principal investigator
remained blinded in the study.
Statistical analysis was planned at the end of stipulated time or after 170
patients had gone through the procedure, whichever came earlier.
Considering a p value of .05 the results was to be analyzed. A total of 44
patients were accrued at the end of the stipulated time period.
Clearance was obtained from the Institutional Review Board (IRB)
and from the ethics committee, for the conduct of the study. As the
department of Urology has two units with different antibiotic
protocols the patients were sub stratified into two groups. The
patients operated in unit 1 received 1 Gm of Augmentin and
Ceftazidime each at surgery. Those operated in unit 2 did not
receive any antibiotic. All were randomized into the placebo or
antimicrobial group. The placebo used was normal saline. The
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contents of commercially available Gentamicin were repackaged in
glass vials in the institutional pharmacy and sterilized. These had a
shelf life of six months. Gentamicin being a clear solution was
indistinguishable from the normal saline, which was also packaged
in similar glass vials with exactly similar labeling. The labeling
differed only in the serial number of each vial, which ranged from
1 to 88, in two sets. These vials sere then placed into plastic bags
of 5 each and each set assigned to one of the two cardboard boxes.
Box 1 was used for Unit-1 transplants and the Box 2 for Unit-2
transplants.
The per-operative antibiotic protocols existing in both units were
strictly adhered to, during the course of the study. All patients had
a documented negative urine culture as laid down in the protocol.
Once the patient was anaesthetized the bladder was washed with
50 ml of normal saline and a 10 ml aliquot was collected in a
sterile container and sent for culture. The bladder was then
distended with saline or saline mixed with 240 mg of gentamicin
unknown to the author who was present, personally instilling the
solution.
The solution for instillation was constituted in the following
manner: while the patient was being draped, 250 mls of I.V normal
saline was placed a large kidney tray and the floor nurse, unaware
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of the actual contents of the vial, broke the seal of the vial and
poured its contents into the kidney tray after meticulously checking
the serial number and the package of origin of the vial. The
antibiotic protocol was uniformly adhered to in each group
preoperatively. As is practiced, patients in Unit-1 received a single
per-operative dose of 1 Gm Ampicillin and Sulbactam and 1 Gm
Ceftazidime just prior to commencement of surgery. Patients in
Unit- 2 received no antibiotic. The principal investigator and the
patient were blinded to the study and were unaware as to who
received the antimicrobial or placebo. The catheter was clamped
and was released at the beginning of ureteroneocystostomy.
The Foley’s catheter was removed once the urine output fell below
5000mls or on the following Monday (the day when patients are
traditionally shifted back to the ward), whichever was later. The
first culture sample was taken on the morning of the day one
following catheter removal. This was a clean catch midstream
sample, which was collected in the ward under supervision of the
ward nurse. The cultures were repeated weekly for the next 12
weeks.  The collection process was carried out under the
supervision of the nurse or the doctor at around 12 noon on
Wednesdays. This procedure was repeated every Wednesdays or
when a UTI was suspected.
30
The patients were then followed up for 12 weeks. Culture
positivity, febrile UTI, and other infections were documented.
31
RESULTS AND ANALYSIS
Table 1. Drug group and infection
Crosstab
10 11 21
47.6% 52.4% 100.0%
10 10 20
50.0% 50.0% 100.0%
20 21 41
48.8% 51.2% 100.0%
Count
% within Drug group
Count
% within Drug group
Count
% within Drug group
placebo
drug
Drug group
Total
no yes
Infection
Total
Chi-Square Tests
.023b 1 .879
.000 1 1.000
.023 1 .879
1.000 .563
.023 1 .880
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Pearson Chi-Square
Continuity Correction a
Likelihood Ratio
Fisher's Exact Test
Linear-by-Linear
Association
N of Valid Cases
Value df
Asymp. Sig.
(2-sided)
Exact Sig.
(2-sided)
Exact Sig.
(1-sided)
Computed only for a 2x2 tablea. 
0 cells (.0%) have expected count less than 5. The minimum expected count is
9.76.
b. 
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Table 2. Per operative antibiotic use * Infection
Crosstab
9 9 18
50.0% 50.0% 100.0%
11 12 23
47.8% 52.2% 100.0%
20 21 41
48.8% 51.2% 100.0%
Count
% within Prior
Antibiotic use
Count
% within Prior
Antibiotic use
Count
% within Prior
Antibiotic use
no
yes
Prior Antibiotic
use
Total
no yes
Infection
Total
Chi-Square Tests
.019b 1 .890
.000 1 1.000
.019 1 .890
1.000 .570
.019 1 .891
41
Pearson Chi-Square
Continuity Correction a
Likelihood Ratio
Fisher's Exact Test
Linear-by-Linear
Association
N of Valid Cases
Value df
Asymp. Sig.
(2-sided)
Exact Sig.
(2-sided)
Exact Sig.
(1-sided)
Computed only for a 2x2 tablea. 
0 cells (.0%) have expected count less than 5. The minimum expected count is
8.78.
b. 
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Table 3. Drug group * Infection in the first week
Crosstab
15 6 21
71.4% 28.6% 100.0%
13 7 20
65.0% 35.0% 100.0%
28 13 41
68.3% 31.7% 100.0%
Count
% within Drug group
Count
% within Drug group
Count
% within Drug group
placebo
drug
Drug group
Total
no yes
Infection in the first
week
Total
Chi-Square Tests
.196b 1 .658
.011 1 .915
.196 1 .658
.744 .457
.191 1 .662
41
Pearson Chi-Square
Continuity Correction a
Likelihood Ratio
Fisher's Exact Test
Linear-by-Linear
Association
N of Valid Cases
Value df
Asymp. Sig.
(2-sided)
Exact Sig.
(2-sided)
Exact Sig.
(1-sided)
Computed only for a 2x2 tablea. 
0 cells (.0%) have expected count less than 5. The minimum expected count is
6.34.
b. 
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Table 4. Drug group * Infection in the second week
Crosstab
15 6 21
71.4% 28.6% 100.0%
15 5 20
75.0% 25.0% 100.0%
30 11 41
73.2% 26.8% 100.0%
Count
% within Drug group
Count
% within Drug group
Count
% within Drug group
placebo
drug
Drug group
Total
no yes
Infection in the second
week
Total
Chi-Square Tests
.067b 1 .796
.000 1 1.000
.067 1 .796
1.000 .538
.065 1 .799
41
Pearson Chi-Square
Continuity Correction a
Likelihood Ratio
Fisher's Exact Test
Linear-by-Linear
Association
N of Valid Cases
Value df
Asymp. Sig.
(2-sided)
Exact Sig.
(2-sided)
Exact Sig.
(1-sided)
Computed only for a 2x2 tablea. 
0 cells (.0%) have expected count less than 5. The minimum expected count is
5.37.
b. 
35
Table 5. Drug group * Infection in the third week
Crosstab
18 3 21
85.7% 14.3% 100.0%
16 4 20
80.0% 20.0% 100.0%
34 7 41
82.9% 17.1% 100.0%
Count
% within Drug group
Count
% within Drug group
Count
% within Drug group
placebo
drug
Drug group
Total
no yes
Infection in the third
week
Total
Chi-Square Tests
.236b 1 .627
.005 1 .943
.237 1 .627
.697 .471
.230 1 .631
41
Pearson Chi-Square
Continuity Correction a
Likelihood Ratio
Fisher's Exact Test
Linear-by-Linear
Association
N of Valid Cases
Value df
Asymp. Sig.
(2-sided)
Exact Sig.
(2-sided)
Exact Sig.
(1-sided)
Computed only for a 2x2 tablea. 
2 cells (50.0%) have expected count less than 5. The minimum expected count is
3.41.
b. 
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Table 6. Per-operative Antibiotic use * Infection in the first week
Crosstab
13 5 18
72.2% 27.8% 100.0%
15 8 23
65.2% 34.8% 100.0%
28 13 41
68.3% 31.7% 100.0%
Count
% within Prior
Antibiotic use
Count
% within Prior
Antibiotic use
Count
% within Prior
Antibiotic use
no
yes
Prior Antibiotic
use
Total
no yes
Infection in the first
week
Total
Chi-Square Tests
.229b 1 .632
.020 1 .888
.230 1 .631
.742 .447
.223 1 .637
41
Pearson Chi-Square
Continuity Correction a
Likelihood Ratio
Fisher's Exact Test
Linear-by-Linear
Association
N of Valid Cases
Value df
Asymp. Sig.
(2-sided)
Exact Sig.
(2-sided)
Exact Sig.
(1-sided)
Computed only for a 2x2 tablea. 
0 cells (.0%) have expected count less than 5. The minimum expected count is
5.71.
b. 
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Table 7. Per-operative Antibiotic use * Infection in the second
week.
Crosstab
15 3 18
83.3% 16.7% 100.0%
15 8 23
65.2% 34.8% 100.0%
30 11 41
73.2% 26.8% 100.0%
Count
% within Prior
Antibiotic use
Count
% within Prior
Antibiotic use
Count
% within Prior
Antibiotic use
no
yes
Prior Antibiotic
use
Total
no yes
Infection in the second
week
Total
Chi-Square Tests
1.688b 1 .194
.891 1 .345
1.747 1 .186
.291 .173
1.647 1 .199
41
Pearson Chi-Square
Continuity Correction a
Likelihood Ratio
Fisher's Exact Test
Linear-by-Linear
Association
N of Valid Cases
Value df
Asymp. Sig.
(2-sided)
Exact Sig.
(2-sided)
Exact Sig.
(1-sided)
Computed only for a 2x2 tablea. 
1 cells (25.0%) have expected count less than 5. The minimum expected count is
4.83.
b. 
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Table 8. Per-operative Antibiotic use  * Infection in the third week.
Crosstab
15 3 18
83.3% 16.7% 100.0%
19 4 23
82.6% 17.4% 100.0%
34 7 41
82.9% 17.1% 100.0%
Count
% within Prior
Antibiotic use
Count
% within Prior
Antibiotic use
Count
% within Prior
Antibiotic use
no
yes
Prior Antibiotic
use
Total
no yes
Infection in the third
week
Total
Chi-Square Tests
.004b 1 .951
.000 1 1.000
.004 1 .951
1.000 .642
.004 1 .952
41
Pearson Chi-Square
Continuity Correction a
Likelihood Ratio
Fisher's Exact Test
Linear-by-Linear
Association
N of Valid Cases
Value df
Asymp. Sig.
(2-sided)
Exact Sig.
(2-sided)
Exact Sig.
(1-sided)
Computed only for a 2x2 tablea. 
2 cells (50.0%) have expected count less than 5. The minimum expected count is
3.07.
b. 
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Table 9. Native kidneys and infection
Poor Prognostic factors * Infection Crosstabulation
19 15 34
55.9% 44.1% 100.0%
1 6 7
14.3% 85.7% 100.0%
20 21 41
48.8% 51.2% 100.0%
Count
% within Poor
Prognostic factors
Count
% within Poor
Prognostic factors
Count
% within Poor
Prognostic factors
no
yes (DM / FSGS)
Poor Prognostic
factors
Total
no yes
Infection
Total
Chi-Square Tests
4.020b 1 .045
2.528 1 .112
4.410 1 .036
.093 .053
3.922 1 .048
41
Pearson Chi-Square
Continuity Correction a
Likelihood Ratio
Fisher's Exact Test
Linear-by-Linear
Association
N of Valid Cases
Value df
Asymp. Sig.
(2-sided)
Exact Sig.
(2-sided)
Exact Sig.
(1-sided)
Computed only for a 2x2 tablea. 
2 cells (50.0%) have expected count less than 5. The minimum expected count is
3.41.
b. 
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Table 10. Kaplan-Meier survival curve for time to infection
Survival Function
Time to first infection
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RESULTS
There were 23 patients in unit 1 and 21 from unit 2. The mean age
of patients in unit 1 was 34.3 years with a range between 14 and 55
years. The mean age of recipients in Unit 2 was 35.7 years with a
range between 20 to 61 years. There were 4 female recipients
in unit 1 and 5 in unit 2. Therefore the demographics remained
matched in both units in terms of age and gender. All patients
received Tacrolimus based immunosuppression.
In all, there were 41 patients available for analysis. Two patients
had graft nephrectomy in the first week and one patient died of
non-septic complications in the second week. Eleven out of 21
patients had a positive urine culture that needed treatment in the
first 3 months of transplant. In the 20 patients who underwent
instillation 10 patients developed UTI. Nine (50%) of the 18
patients who did not have a per-operative of antibiotic at surgery
developed UTI. This was similar to the Unit 1 group, which
received a dose of antibiotic prior to surgery on the operating table.
Twelve of the 23 patients from this unit developed urinary
infection in the first 12 weeks.
Seven of the patients had either Diabetes or FSGS of who 6
contracted UTI. All four diabetics and 2 of the 3 FSGS patients
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developed UTI.
A comparative analysis of the incidence of UTI at the end of first
through third weeks in the gentamicin instillation group vs.
placebo and the group that received per-operative dose of
antibiotic versus those who did not, revealed no significant
advantage for the intervention groups against the non-intervention
groups. ( Tables 3-8)
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DISCUSSION
Aminoglycosides are effective  antimicrobials in urinary tract
infections but the fact that they are nephrotoxic precludes their use
in renal failure patients especially via the parenteral route. Hence
we analyzed if direct instillation of Gentamicin solution delayed
the onset of UTI. Seven of the 20 who received Gentamicin
instillation developed UTI at the end of first week whereas only 6
of the 21 who received placebo had the infection in the first week.
However this did not achieve statistical significance (Tab 2).
Neither did it delay the onset in subsequent weeks. Though not the
primary objective we also looked at whether prior dose of
antibiotic at surgery made a difference. The incidence of UTI in
the Unit 1 group was no different from the Unit 2 group, which did
not receive a dose of antibiotic on table, before surgery (table 1)
the incidence of UTI in the subsequent weeks were also similar in
both groups with neither Gentamicin instillation or prior antibiotic
use making any difference.
 Among the predisposing factors that may have affected the
incidence of UTI, it was found that those with native disease of
Diabetes Mellitus and FSGS had a higher incidence of UTI. This
was statistically significant.
The time of onset of UTI was assessed in all patients across the
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board. A Kaplan-Meier curve was drawn to analyze the time to
infection. Interestingly majority of patients, who developed UTI,
developed it in the first 6 weeks. Of these, more than 30%
developed the infection at the end of the first week. This study
showed that in any patient who did not develop UTI in the first 6
weeks, the chances of him/her developing the infection
subsequently was negligible. This was in concordance with
observations by Rubin (82). He categorized infections as those
occurring within 1 month, 2-6 months, and thereafter. The first
group included urinary infections, vascular access, catheter, and
surgery related infections. A timetable for infections in renal
transplant recipients, was published earlier from our institution,
further validates these observations (83).
THE SPECTRUM
E coli was the most common organism. Klebsiella and
pseudomonas was the next most common in two patients each.
Enterococcus was found in one patient and was a mixed infection,
combined with E coli. One patient had a mixed klebsiella-
pseudomonas infection in the first week. Overall 13 (33%) patients
were found to have bacteriuria following the first week of renal
transplant.
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Weeks Wk 1 Wk 2 Wk 3 Wk 4 Wk 5 Wk 6
E coli 12 10 4 5 5 4
Klebsiella 1 2 1 0 1 1
Pseudo 1 2 0 1 1 1
Enterobact 1 0 0 0 0 0
Table 1: Spectrum of infections. The figures in boxes show no. of patients.
 Under standard immunosuppression, a median of about 50%
(range 6-86%) of all renal transplant recipients develop an
infection within the first 6 months after engraftment. It is known
that urinary tract infections are most common, with an incidence
upto greater than 30% and a relatively high rate of bacteremia and
overt pyelonephritis of the allograft (84). Infections in renal
transplant recipients are therefore of major clinical as well as
economical importance, and are one of the dominating causes of
transplant loss and patient death. In a mortality study by West et al,
(85) infections accounted for 22% of all deaths among renal
transplant patients; this was even higher than myocardial
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infarction, which caused 17%.
Urinary tract infections following transplant may be the result of
indwelling catheter and or anatomic obstructions caused due to the
surgery, particularly ureteroneocystostomy (84). Parenteral
antimicrobial prophylaxis of the urinary infection associated with
urethral catheterization in the post renal transplant period has been
employed many transplant centers. There is a world trend towards
the reduction of the use of this prophylaxis. When used, it needs to
be initiated immediately before the surgery and if continued should
not be used for more than 24 hours after the transplant (85)
Systemic antimicrobial prophylaxis has not been demonstrated to
be of value for the prevention of this infection. Besides,
immunosuppression does not damage the natural defenses of the
host when it is used over a few days in the renal post-transplant
period and the immune system plays no part either in the bladder
colonization or in asymptomatic bacteriuria (86). The
asymptomatic bacteriuria is by far the most frequent infection after
renal transplantation and can cause considerable morbidity when it
is associated with urological, surgical or serious immune
complications (87). Therefore this study was a part of yet another
attempt to look for intervention to reduce such morbidity.
The number of days patients remain on indwelling catheter post
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transplant is not standardized. There is a trend towards early
removal of catheter with most centers stopping continuous bladder
drainage by the fourth day (88). In this study the median period of
catheterization was about 5 days, which is longer than mentioned
in the literature. This probably explains why this study had a
higher incidence of urinary infections in the first few weeks
following transplant. This longer period of urethral catheterization
may cause greater harm to the normal urethral flora and may lead
to a higher incidence of urinary infection (85,89). 
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CONCLUSIONS
Gentamicin instillation into the bladder at a dose of 240 mgs
during transplant surgery did not appear to provide any protection
from urinary tract infections post operatively at any point in time.
Per operative dose of Augmentin and Ceftazidime also did not
make any impact on the incidence of postoperative urinary tract
infections.
Diabetics and those with focal segmental glomerulosclerosis
appear to be at a greater risk of developing post transplant urinary
tract infections.
However studies with a larger sample size are required to draw any
statistically significant conclusions.
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LIMITATIONS
This study had a major limitation in that patient accruals were
inadequate. The number of patients enrolled fell short of the
minimum sample size required. Hence it is possible that the
interventions studied may have achieved statistical significance in
a larger group of patients.
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Patient name Hospi Seria uni wt Date Sx pre On post c/s antibiot Imm Indu NKD wk1 wk2 wk3 wk4 wk5 wk6 wk62 wk7 wk8 wk9 wk10 wk11 wk12 Colu
Anand Nayak 6471 5s 2 4/19/2007 No NG T,M, none CAN Pseu/kl pseu NG conta NG NG NG NG pseud pseu klebs NG NG
Tapan Banik 2782 18s 2 46 11/13/2007 neg NG T,M, ATG CIN NG NG NG NG NG NG NG EC
NG NG NG NG NG
ATT 
Helal Ahmed 9644 10 1 52.5 5/15/2007 contam NG augme T,M, none diffu NG NG NG NG NG NG NG NG NG NG NG NG NG
Dasho Tsetrim 5066 2 1 3/27/2007 contam NG augme T,M, none DM NG contamin contami contamin 11,000 EC NG NG NG NG NG NG NO 
Somnath M 9967 13s 2 43 7/4/2007 no NG T,M, ATG DM E coli E coli Ecoli E coli NG NG NG E coli E-coli Klebsi Klebsiella Klebsiell Klebsie
Pattabhi Reddy 6415 15s 2 9/19/2007 neg NG T,M, ATG DM NG NG NG
NG NG NG NG NG NG NG NG NG NG
Shrikant Pd 9854 18 1 10/9/2007 neg NG augme T,M, IL-2 DM EC EC EC EC EC EC EC EC EC EC EC EC EC Post 
Jaman Gurung 6848 21 1 51.8 11/8/2007 neg NG augme T,M, none DM NG EC, PA cont Pseud cont Pseud Pseu pseud pseud Febri
Laboni Pati 9376 13 1 41 6/20/2007 no NG augme T,M, IL-2 fsgs E coli E coli NG 7/11 cont cont NG NG E-coli 
NG NG NG NG NG
Febri
Bhishma Raj 0034 14 1 55 7/17/2007 contam NG augme T,A, none FSG NG
NG NG NG NG NG NG NG NG NG NG NG NG
Raj Kumar 0312 16s 2 10/3/2007 neg NG T,M, none FSG NG NG ####### ###### EXP
Salomi Ao 0888 19s 2 43 11/14/2007 neg NG TMP IL-2 FSG NG NG NG E Coli
NG NG
E coli E coli
Dipa Dutta 9841 8s 2 34 5/25/2007 contam NG T,A, none hype E coli E coli, NG 6/14 NG 6/21 E coli E coli E coli E coli E coli E coli E coli E coli E coli Had 
Nanda Kishore 3297 6 1 4/11/2007 No NG augme T,M, none MPG NG NG NG NG NG NG NG NG NG NG NG NG NG
Hemant Singh 9548 1 1 No NG No augme T,M, none UK NG NG NG NG NG NG NG NG NG NG NG NG NG
Kavita Kumari 3512 3 1 3/28/2007 contam NG augme T,A, none UK Entero, E.coli, E.coli, NG E.coli, E.coli, E.coli, NG NG NG NG NG NG UTI, 
Tshering W 9683 1s 2 39.5 3/29/2007 staph NG augme T,M, IL-2 UK E.coli, NG NG NG NG NG NG NG NG NG NG NG NG one 
Fazlul Sumon 8743 4 1 69.2 4/3/2007 cont NG augme T,M, none UK E.coli, E coli E coli E coli E coli E coli E coli E coli Persi
Chewang 3430 2s 2 4/4/2007 No NG T,M, none UK NG NG Kleb NG NG NG NG NG NG NG Candida A NG NG Prolo
Mau 7808 3s 2 4/5/2007 No NG T,M, none UK NG NG NG NG NG Klebs Cont Cont Cont Cont Cont Cont Cont
Sohrab Ali 9787 5 1 63.6 4/10/2007 No NG augme T,M, none UK NG NG NG NG NG NG NG NG Cont NG NG NG NG
Wangdup 8261 4s 2 53.4 4/12/2007 No NG T,M, none UK NG NG NG NG NG NG NG NG NG NG NG NG NG
Subramani 9943 7 1 4/17/2007 No NG augme T,M, none UK NG NG Cont, NG NG NG NG NG MOA MOA NG NG NG
Kishore Gurung 9314 8 1 50.2 4/24/2007 contam NG augme T,M, none UK E-coli NG E-coli NG NG NG E coli NG NG NG NG NG NG
Kaushik Roy 9854 9 1 53 5/1/2007 No NG augme T,M, none UK NG E-coli, cont Cont NG NG NG NG NG NG NG NG NG
Habiludin 7893 7s 2 5/16/2007 No NG T,M, none UK NG Cont NG NG NG NG NG NG NG NG NG NG NG
Chandrakanta 9934 11 1 50.4 5/23/2007 no NG augme T,M, IL-2 UK E coli, E coli cont cont cont cont cont cont cont cont cont cont cont  UTI 
VANLALROTLU 0055 12 1 51 6/5/2007 no NG augme T,M, IL-2 UK NG NG NG NG NG NG NG NG NG NG NG NG NG
Mohd Abdur 4181 9s 2 53 6/13/2007 no NG T,M, IL-2 UK NG NG NG NG NG NG NG NG NG NG NG NG NG
Tarun Kumar 8902 10s 2 6/14/2007 no NG T,M, IL-2 UK NG NG NG NG NG NG NG NG NG NG NG NG NG
Dhan Bahadur 0292 11s 2 59 6/27/2007 contam NG sepsis, T,M, IL-2 UK NG NG NG NG NG NG NG NG NG NG NG NG NG NG
Gostha Gopal 0223 12s 2 57 6/28/2007 no NG fever, T,M, none UK NG NG NG NG NG NG NG NG NG NG NG NG NG
Masud Rana 9808 14s 2 7/18/2007 no NG T,M, none UK NG NG NG NG NG NG NG NG NG NG NG NG NG
Shikha 8586 15 1 14 7/31/2007 contam NG augme T,M, none UK NG NG NG NG NG NG NG NG NG NG NG NG NG
NG
Amarendra 0040 16 1 15 8/21/2007 no NG augme T,A, none UK EC, EC EC 9/17 EC 9/29 cont EC cont NG NG NG cont NG NG No 
Yaiphaba L 0324 17 1 58 9/18/2007 no NG augme T,M, none UK NG NG NG NG NG NG NG NG NG NG NG NG Klebsie Reje
Manas Kundu 0025 19 1 11/6/2007 neg NG augme T,M, none UK NG NG NG NG NG NG NG NG NG NG NG NG NC
Tshering Dorji 0753 20 1 11/7/2007 neg NG augme T,M, IL-2 UK EC EC 11/19 NG 11/26 NG 1/12 EC 12/6 EC Ec EC NG NG NG NG Febri
John Moses 0470 22 1 45.8 11/27/2007 neg NG augme TAP IL-2 UK NG NG NG NG NG NG NG NG NG Post 
Md Zahane 1370 23 1 62.9 12/18/2007 cont NG augme TMP IL-2 UK NG NG NG NG NG NG NG NG NG
Amire sultana 1346 21s 2 39.4 12/20/2007 cont NG TMP IL-2 UK NG NG NG NG NG NG NG NG NG
Humayun Kabir 9922 17s 2 10/31/2007 neg NG T,M, IL-2 UK , NG 0 o o o o o o o o o o o
Jitendra 9871 6s 2 5/10/2007 contam NG T,M, IL-2 VUR E.coli NG E-coli E-coli cont cont cont E coli E coli, cont cont NG NG frequ
Md Firoz Alam 1155 20s 2 60 11/28/2007 neg NG TMP IL-2 NG
NG NG NG NG
1Informed consent for patients in the Gentamicin instillation study
Introduction
Hello, I am Dr Ajit J Thomas working in the Department of
urology, CMC, Vellore. We are conducting a study, which we
hope, will help us to lower the incidence of urinary tract infection
following renal transplant. Currently post op urinary infections
cause significant morbidity to the renal transplant patient, even
causing the graft dysfunction. We believe instillation of dilute
Gentamicin in urinary bladder might lower the post op incidence of
urinary infections.
The study is entitled “Does intravesical instillation of Gentamicin
during renal transplantation lower the incidence of postoperative
urinary infections?”
Study procedure
 If you participate, we will collect your medical history and check
for your eligibility based on the records. If eligible you will be
randomized into either of 2 groups. One group will have plain
normal saline instilled at surgery and the other group will have 240
mg of gentamicin mixed to the normal saline before its instillation
into the bladder. The fluid will remain in the bladder till the
catheter is unclamped at he end of the ureteric implant.
Benefits
A possible reduction in the incidence of urinary infections is
anticipated.
2Risks
The risks are minimal, as it does not involve injection into your
body. Most studies done on animals and humans do not show
appreciate amounts of absorption into the body.
Compensation
You will not be entitled to any compensation for participating in
the
Study
Confidentiality
Your name will not appear on the study record. Information
regarding you will be kept a secret and only accessed for results
and analysis of data.
Participation
Your participation is voluntary. You may withdraw from the study
at any point in time before surgery. This will not affect your future
treatment in the hospital. The investigator may also withdraw you
from the study without your consent.
Reporting your experience
If you have had any bad experience, which you think may have
been due to the drug, kindly feel free to contact Dr Ajit J Thomas
at this no. 9944166911
I would like to know if you have understood my explanations and
if you have any queries before participating in the study. If you
agree to take part kindly sign or place your thumb impression on
this document below.
3Participants’ statement
It has been informed to me in the language that I understand that
this is a study being conducted to see if instilling Gentamicin into
my bladder will alter the incidence of postoperative urinary tract
infection.
I am aware that the study involves my randomization to either of
the two groups depending on numbers generated by the computer.
I’m aware that at the time of undergoing the surgery for renal
transplant, I may or may not have diluted Gentamicin instilled in
my bladder for a period of surgery; depending on which group
I’m allocated to. The fluid containing gentamicin shall be
removed at the end of surgery.
I am aware of the side effects of this drug when administered by
injection. I have been assured that it does not involve injection of
the drug into my body and there is only negligible amount of
absorption of the drug when instilled as a dilute solution (240mg
in 300 Normal saline) in the bladder.
I have read the consent document and have discussed with Dr Ajit
J Thomas, the procedure described in the information sheet. I have
had the opportunity to ask questions which have been answered to
my satisfaction. I understand that any questions I may have asked
will be answered verbally or if I prefer with a written statement.
I am aware that the participation is purely voluntary and does not
involve any compensation. I may withdraw from the study at any
time without assigning any reason, and this will have no bearing on
the treatment in future in this institution.
4I understand that any illness arising out of the consequence of
Gentamicin instillation will be treated free of cost but I shall bear
all other expenses.
If I have any questions regarding my rights , I may contact IRB in
CMC, Vellore.
I am fully informed about the risks and benefits and hereby
consent to the procedures set forth above.
I understand that my identity as a participant in the study, and my
medical records and data will be kept confidential, except as
required by law and for inspection by the study supervisors.
Date                                                      Signature of participant
I   have fully explained to, the nature of the study and its attendant
risks and benefits. I have answered all the questions to the best of
my ability and knowledge.
Signature of investigator                                  Signature of witness
